Vanda Pharmaceuticals Inc. (VNDA)
$6.39
$-1.05
(-14.11%)
As on 07-May-2026 16:00EDT
Market cap
$447 Mln
Revenue (TTM)
$216 Mln
P/E Ratio
--
P/B Ratio
1.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.8
-
Debt to Equity
0
-
Book Value
$5.5
-
EPS
$-3.7
-
Face value
--
-
Shares outstanding
60,135,062
10 Years Aggregate
CFO
$157.52 Mln
EBITDA
$-67.70 Mln
Net Profit
$152.78 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
| -27.6 | -8.3 | -11.6 | 46.2 | -2.8 | -18.3 | -2.9 |
|
BSE Sensex*
| -8.7 | 3.6 | -7.5 | -4.2 | 8.2 | 9.5 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
| 84.1 | 13.4 | -42.9 | -52.9 | 19.4 | -19.9 | -37.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
6.4 | 447.4 | 216.1 | -220.5 | -64.1 | -50.9 | -- | 1.4 |
| 78.0 | 11,082.2 | 1,091.0 | 202.3 | 31.6 | 31.3 | 49.5 | 18.5 | |
| 246.1 | 14,573.8 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 78.1 | |
| 46.2 | 12,241.0 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.1 | 5.2 | |
| 92.3 | 12,229.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 296.7 | 8,519.4 | 389.1 | 204.8 | 41.5 | 18.9 | 38.7 | 6.6 | |
| 534.9 | 12,443.8 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.8 | |
| 428.7 | 12,189.0 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.9 | 19.9 | |
| 102.4 | 8,234.3 | 0.0 | -425.4 | -- | -36.7 | -- | 6.5 | |
| 333.3 | 9,422.8 | 0.0 | -303.3 | -- | -45.8 | -- | 10.7 |
Shareholding Pattern
View DetailsAbout Vanda Pharmaceuticals (VNDA)
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic... or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia. Address: 2200 Pennsylvania Avenue NW, Washington, DC, United States, 20037 Read more
-
Founder, President, CEO & Chairman of The Board
Dr. Mihael H. Polymeropoulos M.D.
-
Founder, President, CEO & Chairman of The Board
Dr. Mihael H. Polymeropoulos M.D.
-
Headquarters
Washington, DC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Vanda Pharmaceuticals (VNDA)
What is the current share price of Vanda Pharmaceuticals Inc (VNDA) Today?
The share price of Vanda Pharmaceuticals Inc (VNDA) is $6.39 (NASDAQ) as of 07-May-2026 16:00 EDT. Vanda Pharmaceuticals Inc (VNDA) has given a return of -2.76% in the last 3 years.
What is the current PB & PE ratio of Vanda Pharmaceuticals Inc (VNDA)?
Since, TTM earnings of Vanda Pharmaceuticals Inc (VNDA) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2.36
|
1.59
|
|
2024
|
-14.78
|
0.52
|
|
2023
|
96.77
|
0.45
|
|
2022
|
67.35
|
0.80
|
|
2021
|
27.09
|
1.78
|
What is the 52 Week High and Low of Vanda Pharmaceuticals Inc (VNDA)?
The 52-week high and low of Vanda Pharmaceuticals Inc (VNDA) are Rs 9.94 and Rs 3.81 as of 08-May-2026.
What is the market cap of Vanda Pharmaceuticals Inc (VNDA)?
Vanda Pharmaceuticals Inc (VNDA) has a market capitalisation of $ 447 Mln as on 07-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Vanda Pharmaceuticals Inc (VNDA)?
Before investing in Vanda Pharmaceuticals Inc (VNDA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.